Electra Therapeutics
ETRA

Electra Therapeutics (ETRA) analyst forecast and price target

Analyst forecast

Buy

Consensus of 6 analyst ratings

Buy
6
Hold
0
Sell
0
Average price target
$33.50+274.72% vs. last price
Last $8.94
Low $30.00High $36.00

Based on 4 analyst targets

6 firms have rated Electra Therapeutics (ETRA) in the last 3 months: 6 buy, 0 hold and 0 sell. Their average 12-month price target is $33.50, 284.6% above a share price of $8.71, ranging from $30 (HC Wainwright & Co.) to $36 (2 firms). No firm has changed its rating in that time.

Recent analyst ratings

Last 3 months
FirmActionRatingPrice targetDate
HC Wainwright & Co.Initiated CoverageBuy$30.00Oct 23, 2026
JP MorganInitiated CoverageOverweight$36.00Oct 22, 2026
TD CowenInitiated CoverageBuy—Oct 13, 2026
Cantor FitzgeraldInitiated CoverageOverweight—Oct 13, 2026
Evercore ISI GroupInitiated CoverageOutperform$36.00Oct 13, 2026
JefferiesInitiated CoverageBuy$32.00Oct 13, 2026

Frequently asked questions

  • What is the price target for ETRA stock?

    The average 12-month analyst price target for Electra Therapeutics (ETRA) is $33.50, with a high estimate of $36.00 and a low of $30.00, across 4 analysts.

  • Is ETRA a buy, sell, or hold?

    Analysts covering Electra Therapeutics currently average a Buy rating: 6 buy, 0 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.

  • What upside do analysts see for ETRA?

    The average price target of $33.50 implies 274.72% upside from the last price of $8.94.

  • Who has the highest and lowest price target for ETRA?

    Among the price targets analysts have published for Electra Therapeutics in the last 3 months, the highest is $36.00 from JP Morgan and Evercore ISI Group and the lowest is $30.00 from HC Wainwright & Co..

  • Has ETRA been upgraded or downgraded recently?

    No. Electra Therapeutics has had no analyst upgrades or downgrades in the last 3 months.

  • What is the latest analyst rating on ETRA?

    On Oct 23, 2026, HC Wainwright & Co. initiated coverage of Electra Therapeutics at Buy with a price target of $30.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.